2024-512634-15-00招募中2 期
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
LYSARC, LYSARC37 个研究点 分布在 2 个国家目标入组 68 人开始时间: 2024年5月21日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 68
- 试验地点
- 37
- 主要终点
- The primary endpoint is the MRD negativity rate at the end of induction (after 6 cycles) in the informative MRD set using ddPCR technique. We expect to have an increase of 12% of the MRD negativity rate in each arm.
研究概览
简要总结
The primary objective is to estimate the minimum residual disease (MRD) rate using droplet digital PCR (ddPCR) in bone marrow and/or peripheral blood at the end of induction (after 6 cycles of Ibrutinib/CD20 Ab and Ibrutinib/CD20 Ab/Venetoclax) in previously untreated MCL patients.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥ 18 years and < 80 years of age at the time of signing the informed consent form (ICF).
- •Stage II-IV disease, measurable with at least lymph node > 1.5 cm and requiring treatment in the opinion of the treating clinician
- •ECOG performance status of 0 –
- •Life expectancy of more than 3 months.
- •For France: patient affiliated to any social security system
- •Patient understood and voluntarily signed and dated an ICF prior to any studyspecific assessments/procedures being conducted.
- •Patient willing and able to adhere to the study visit schedule and other protocol requirements
- •Women of childbearing potential must have negative results for pregnancy test prior to study treatment start and agree to abstain from breastfeeding during study participation and at least 18 months after the last drug administration
- •Men or women of reproductive potential agree to use highly effective method of contraception (failure rate of less than 1%) during treatment and for eighteen months after the last drug administration.
- •Histologically confirmed (according to the WHO classification) mantle cell lymphoma. The diagnosis has to be confirmed by phenotypic expression of CD5, CD20 and cyclin D1 or the t(11;14) translocation (by cytogenetics and/or FISH and/or BCL1-IgH PCR)
- •Untreated MCL
- •Adequate renal function as demonstrated by a creatinine clearance > 50 mL/min; calculated by Cockcroft Gault formula or MDRD
- •Adequate hepatic function per local laboratory reference range as follow: o Aspartate transaminase (AST) and alanine transaminase (ALT) < 3.0 x upper limit of normal (ULN) o Bilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin)
排除标准
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
- •Known history of human immunodeficiency virus (HIV)
- •Evidence of other clinically significant uncontrolled condition(s) including but not limited to: - Uncontrolled and/or active systemic infection (viral, bacterial or fungal) - Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. HBs antigen negative, anti-HBs antibody + and antiHBc antibody -) and subjects with anti- HB-core antibody that are HBV DNA negative may participate
- •Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study
- •Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’ opinion, could compromise the patient safety, interfere with the absorption or metabolism of treatment (Ibrutinib, CD20 Ab, venetoclax) or put the study outcomes at undue risk
- •Pregnant, planning to become pregnant, or lactating woman
- •Known hypersensitivity to study treatment (CD20 Ab, Ibrutinib, Venetoclax) or to any of the excipients
- •Known allergy to xanthine oxidase inhibitors or rasburicase
- •Known G6DP deficiency
- •Known bleeding disorders
- •Severe prior reactions to monoclonal antibodies or with prior significant toxicity (other than thrombocytopenia) from Bcl-2 inhibitor
- •Impaired organ function (other than liver and renal) which will interfere with the treatment
- •History of prior other malignancy with the exception of: - curatively treated basal cell carcinoma - curatively treated squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study - other curatively treated cancer and patient disease-free for over 5 years
- •Anti-cancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents
- •Biological agents (e.g. monoclonal antibodies) for anti-neoplastic intent: excluded 30 days prior to first dose of venetoclax
- •Person deprived of his/her liberty by a judicial or administrative decision
- •Adult person under legal protection
- •Hemoglobin level < 10g/dL; Neutrophil count <1 G/L; Platelets < 75 G/L (except if related to lymphoma then platelet must be >50),
- •Major surgery within 28 days before enrollment
- •Known central nervous system lymphoma
- •History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
- •Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumone)
- •Requires treatment with strong CYP3A inhibitors
- •Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID vaccine)
结局指标
主要结局
The primary endpoint is the MRD negativity rate at the end of induction (after 6 cycles) in the informative MRD set using ddPCR technique. We expect to have an increase of 12% of the MRD negativity rate in each arm.
The primary endpoint is the MRD negativity rate at the end of induction (after 6 cycles) in the informative MRD set using ddPCR technique. We expect to have an increase of 12% of the MRD negativity rate in each arm.
次要结局
- PFS at 3 years. We expect to have an increase of 10% of the PFS at 3 years in each arm.
研究者
Steven Le Gouill
Scientific
LYSARC
研究点 (37)
Loading locations...
相似试验
尚未招募
不适用
Minimal Residual Disease in Solid MalignanciesBreast CancerProstate CancerGastric CancerNCT07268469European Institute of Oncology840
招募中
不适用
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital StoriesNCT07263074University of Rochester120
招募中
2 期
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72
招募中
3 期
Extension Study for Participants in Studies That Include Pembrolizumab2022-501254-10-00Merck Sharp & Dohme LLC1,133
招募中
2 期
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple MyelomaMultiple Myeloma2023-506587-13-00Janssen - Cilag International56